Healthcare Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
Bahrain Pharmaceuticals and Healthcare Report Q1 2015

Bahrain Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: Our outlook for Bahrain's pharmaceutical and healthcare sector remains strong, with the
government announcing the development and expansion of health centres across the country in addition to
several preventive health projects planned. Despite recent price cuts negatively impacting the market in the
short term, we believe an ageing population, increasing chronic disease burden and robust economic
growth will drive medicine demand for many years to come.
Headline Expenditure Projections

$1,295.00
Bangladesh Pharmaceuticals and Healthcare Report Q1 2015

Bangladesh Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: Chronic diseases will become a key healthcare challenge for Bangladesh over the next decade.
Driven by the country's ageing population, urbanisation and inadequate treatment of non-communicable
diseases, this represents an epidemiological transition that will present new opportunities for
pharmaceutical companies.
Headline Expenditure Projections
■ Pharmaceuticals: BDT138.81bn (USD1.78bn) in 2013 to BDT154.62bn (USD1.99bn) in 2014; +11.4%
in local currency terms and +11.9% in US dollar terms

$1,295.00
Belarus Pharmaceuticals and Healthcare Report Q1 2015

Belarus Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: The Belarusian market will suffer from the impact of depreciation and economic instability as
the country's economy becomes ever more reliant on Russian loans to function. Furthermore, wage growth
mandated by the government will become unsustainable, threatening to dampen internal consumption.
Belarus will present little reward for high risk for most pharmaceutical companies in the region.
Headline Expenditure Projections
Pharmaceuticals: BYR8,927bn in 2013 (USD1.00bn) to BYR11,490bn (USD1.09bn) in 2014; +28.7% in

$1,295.00
China Pharmaceuticals and Healthcare Report Q1 2015

China Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: Improvements in intellectual property protection, an ageing population and increasing access
to healthcare will drive the robust growth of China's pharmaceutical market. This will attract foreign drug
manufacturers despite the downside risks of pharmaeconomics and the government's crackdown on illegal
practices.
Headline Expenditure Projections
■ Pharmaceuticals: CNY532.4bn (USD86.6bn) in 2013 to CNY616.1bn (USD100.6bn) in 2014; +15.7%
in local currency and +16.1% in US dollar terms.

$1,295.00
Finland Pharmaceuticals and Healthcare Report Q1 2015

Finland Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: Finland, like many other Western countries, has a mature pharmaceutical market where growth
is slowing. Although an ageing population will drive the demand for high-value medicines for the treatment
of long-term illnesses, drug manufacturers will be pressured to reduce drug prices as the government
increases its cost-containment measures. Political uncertainty along with the country's weak economic
outlook adds further downward pressure to our forecast.
Headline Expenditure Projections

$1,295.00
India Pharmaceuticals and Healthcare Report Q1 2015

India Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: The new government under Prime Minister Modi bodes well for the overall pharmaceutical
sector. The proposed introduction of universal healthcare in 2015 coupled with small regulatory reform will
help unlock the potential of the large Indian market.
Headline Expenditure Projections
Pharmaceuticals: INR904.0bn (USD15.4bn) in 2013 to INR1,021.8bn (USD17.0bn) in 2014; +13.0% in
local currency terms and +10.36% in US dollar terms.
Healthcare: INR4,640bn (USD79.2bn) in 2013 to INR5,179.9bn (USD86.3bn) in 2014; +11.6% in local

$1,295.00
Kazakhstan Pharmaceuticals and Healthcare Report Q1 2015

Kazakhstan Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: Plans to boost government spending on healthcare will be positive for the pharmaceutical
industry as well as other participants in the healthcare sector. Over the longer term, the introduction of
compulsory health insurance will create a large pool of funding for further growth. However, a key risk to
our outlook is oil prices and their effect on Kazakh government revenues.
Headline Expenditure Projections
■ Pharmaceuticals: KZT273.92bn (USD1.80bn) in 2013 to KZT335.18bn (USD1.84bn) in 2014; +22.4%

$1,295.00
Philippines Pharmaceuticals and Healthcare Report Q1 2015

Philippines Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: Our outlook for the Philippines' pharmaceutical sector remains bullish, driven by an increasing
population and high burden of disease profile. Generic medicines will continue to account for an increasing
share of pharmaceutical sales in the Philippines, galvanised by expanding government provision of
healthcare as well as improvements in generic drug distribution. This provides strong growth opportunities
for generic drug manufacturers in an emerging market where economic growth will be sustained by robust

$1,295.00
United Kingdom Pharmaceuticals and Healthcare Report Q1 2015

United Kingdom Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: The pharmaceutical and healthcare markets of the United Kingdom are driven by government
spending in the form of the National Health System (NHS), which accounts for over 80% of total healthcare
spending. With a higher prevalence of non-communicable diseases, coupled with an ageing population, the
increased demand for healthcare may lead to the enforcement of cost-containment strategies and movement
away from expensive treatment options.
Headline Expenditure Projections

$1,295.00
Zimbabwe Pharmaceuticals and Healthcare Report Q1 2015

Zimbabwe Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Dec 17 2014

BMI View: The World Health Organization's approval of a quality control laboratory for medicines in
Zimbabwe is a positive step for the country's pharmaceutical market. It will help to reduce the proportion of
counterfeit medicines in circulation and increase the country's attractiveness to multinational drugmakers.
Nevertheless, for the foreseeable future the dire economic and political outlook, reduced healthcare budget
and underdeveloped local manufacturing industry will continue to limit investment.
Headline Expenditure Projections

$1,295.00
Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Date Published: Dec 1 2014

The Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the royalty financing partnering agreements entered into by the worlds leading healthcare companies.

Description
The Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals.

$1,995.00
Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics

Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics

Date Published: Dec 1 2014

The Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

$2,995.00
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

Date Published: Dec 1 2014

The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s biopharma companies

$3,295.00
Gene Therapy Partnering Terms and Agreements

Gene Therapy Partnering Terms and Agreements

Date Published: Dec 1 2014

The Gene Therapy Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

$1,995.00
Cancer Vaccine Partnering Terms and Agreements

Cancer Vaccine Partnering Terms and Agreements

Date Published: Dec 1 2014

The Cancer Vaccine Partnering Agreements Terms and Agreements report provides comprehensive understanding and unprecedented access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

$1,995.00
EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023

Date Published: Dec 1 2014

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023

Summary

$3,995.00
Cancer Diagnostics Partnering Terms and Agreements

Cancer Diagnostics Partnering Terms and Agreements

Date Published: Dec 1 2014

The Cancer Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

$2,995.00
EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

Date Published: Dec 1 2014

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

Summary

Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation of the joints. In RA, the body’s immune system attacks the lining of the joints causing an inflammatory response. RA is characterized by joint swelling, pain, and redness, which can cause bone and cartilage erosion, and joint deformity. The disease can lead to premature mortality, disability, and decreased quality of life.

$3,995.00
EpiCast Report: Acromegaly and Gigantism - Epidemiology Forecast to 2023

EpiCast Report: Acromegaly and Gigantism - Epidemiology Forecast to 2023

Date Published: Dec 1 2014

EpiCast Report: Acromegaly and Gigantism - Epidemiology Forecast to 2023

Summary

Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). GH excess beginning in adulthood is known as acromegaly, whereas GH excess beginning during childhood is known as gigantism.

$3,995.00
Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth

Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth

Date Published: Nov 30 2014
Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 Increasing Uptake of Novel Drug Classes to Drive Market Growth report provides insights into type 2 diabetes in the Asia-Pacific (APAC) markets of China, India, Japan and Australia. The report estimates the market size for 2013 and provides a forecast until 2020, and covers disease epidemiology, treatment algorithms, and treatment use patterns. It also provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals.
$4,995.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data